F A Shepherd

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi request reprint Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review
    Ron Feld
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Thorac Oncol 1:367-76. 2006
  2. doi request reprint Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy
    Frances A Shepherd
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Room 5 103, 610 University Ave, Toronto, Ontario, Canada
    J Clin Oncol 31:2173-81. 2013
  3. doi request reprint [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome]
    Frances A Shepherd
    Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada
    Zhongguo Fei Ai Za Zhi 16:C9-20. 2013
  4. ncbi request reprint Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer
    Frances A Shepherd
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Thorac Oncol 2:S68-76. 2007
  5. ncbi request reprint The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer
    Frances A Shepherd
    Department of Medicine, Division of Medical Oncology and Hematology of the University Health Network, Princess Margaret Hospital and the University of Toronto, Ontario, Canada
    J Thorac Oncol 2:1067-77. 2007
  6. ncbi request reprint Second-line chemotherapy for non-small cell lung cancer
    Frances A Shepherd
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Expert Rev Anticancer Ther 3:435-42. 2003
  7. ncbi request reprint Angiogenesis inhibitors under study for the treatment of lung cancer
    Frances A Shepherd
    Division of Hematology Oncology, Department of Medicine, University Health Network, Princess Margaret Hospital Division, University of Toronto, 610 University Avenue, Suite 5 104, Ont, M5G 2M9, Toronto, Canada
    Lung Cancer 41:S63-72. 2003
  8. ncbi request reprint Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Orga
    Frances A Shepherd
    National Cancer Institute of Canada Clinical Trials Group
    J Clin Oncol 20:4434-9. 2002
  9. ncbi request reprint Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group
    F A Shepherd
    The Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, 5 104, Toronto, Ontario, M5G 2M9, Canada
    Cancer 92:595-600. 2001
  10. doi request reprint Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome
    Frances A Shepherd
    Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada
    J Thorac Oncol 6:1763-73. 2011

Detail Information

Publications117 found, 100 shown here

  1. ncbi request reprint Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review
    Ron Feld
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Thorac Oncol 1:367-76. 2006
    ..In this systematic review, we evaluated the role of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of patients with advanced NSCLC...
  2. doi request reprint Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy
    Frances A Shepherd
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Room 5 103, 610 University Ave, Toronto, Ontario, Canada
    J Clin Oncol 31:2173-81. 2013
    ..We undertook this analysis of KRAS mutation in four trials of adjuvant chemotherapy (ACT) versus observation (OBS) to clarify the prognostic/predictive roles of KRAS in non-small-cell lung cancer (NSCLC)...
  3. doi request reprint [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome]
    Frances A Shepherd
    Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada
    Zhongguo Fei Ai Za Zhi 16:C9-20. 2013
    ..Abstract available from the publisher...
  4. ncbi request reprint Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer
    Frances A Shepherd
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Thorac Oncol 2:S68-76. 2007
    ..It is likely that in the future, clinicians will evaluate a panel of biological markers in order to customize therapy for individual patients with NSCLC...
  5. ncbi request reprint The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer
    Frances A Shepherd
    Department of Medicine, Division of Medical Oncology and Hematology of the University Health Network, Princess Margaret Hospital and the University of Toronto, Ontario, Canada
    J Thorac Oncol 2:1067-77. 2007
    ..The current analysis looks to the impact of the TNM system on the clinical staging of SCLC and of the new International Association for the study of Lung Cancer (IASLC) proposals...
  6. ncbi request reprint Second-line chemotherapy for non-small cell lung cancer
    Frances A Shepherd
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Expert Rev Anticancer Ther 3:435-42. 2003
    ..The results of placebo-controlled randomized trials of this family of drugs are awaited. In summary, several studies have now found a definite role for the second-line treatment of patients with non-small cell lung cancer...
  7. ncbi request reprint Angiogenesis inhibitors under study for the treatment of lung cancer
    Frances A Shepherd
    Division of Hematology Oncology, Department of Medicine, University Health Network, Princess Margaret Hospital Division, University of Toronto, 610 University Avenue, Suite 5 104, Ont, M5G 2M9, Toronto, Canada
    Lung Cancer 41:S63-72. 2003
    ..It is hoped that as our understanding of the complex process of angiogenesis increases, so will our ability to design more effective targeted therapies...
  8. ncbi request reprint Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Orga
    Frances A Shepherd
    National Cancer Institute of Canada Clinical Trials Group
    J Clin Oncol 20:4434-9. 2002
    ..This trial was undertaken to determine whether adjuvant treatment with the metalloproteinase inhibitor marimastat could prolong survival in responding patients with SCLC after chemotherapy...
  9. ncbi request reprint Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group
    F A Shepherd
    The Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, 5 104, Toronto, Ontario, M5G 2M9, Canada
    Cancer 92:595-600. 2001
    ..This study was undertaken to determine the response to pemetrexed disodium given in combination with cisplatin...
  10. doi request reprint Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome
    Frances A Shepherd
    Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada
    J Thorac Oncol 6:1763-73. 2011
    ..In this review, we provide an updated look at the clinical data on immunotherapeutic interventions, which potentiate the immune system's response to lung tumor cells...
  11. ncbi request reprint Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    F A Shepherd
    University of Toronto, Toronto, and London Regional Cancer Centre, London, Ontario, Canada
    J Clin Oncol 18:2095-103. 2000
    ..Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life...
  12. doi request reprint Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer
    Geoffrey Liu
    Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital University Health Network and University of Toronto, Toronto, Canada
    J Thorac Oncol 7:316-22. 2012
    ..Predictive and prognostic analyses of epidermal growth factor receptor (EGFR), ABCG2, and AKT1 genetic polymorphisms were performed...
  13. ncbi request reprint Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
    N Murray
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 17:2300-8. 1999
    ..To determine whether an intensive weekly chemotherapy regimen plus thoracic irradiation is superior to standard chemotherapy in the treatment of extensive-stage small-cell lung cancer (ESCLC)...
  14. ncbi request reprint Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10
    Carmela Pepe
    Division of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    J Clin Oncol 25:1553-61. 2007
    ..This retrospective study evaluated the influence of age on survival, adjuvant chemotherapy delivery, and toxicity in National Cancer Institute of Canada (NCIC) Clinical Trials Group study JBR.10...
  15. doi request reprint Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24
    R Goodwin
    NCIC Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Ann Oncol 21:2220-6. 2010
    ....
  16. doi request reprint Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials
    Timothy R Asmis
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 26:54-9. 2008
    ..The main objective was to determine if age and/or the burden of chronic medical conditions (comorbidity) are independent predictors of survival, treatment delivery, and toxicity...
  17. pmc Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study
    F A Shepherd
    Interdepartmental Division of Oncology of the University of Toronto, Ontario, Canada
    Br J Cancer 78:683-5. 1998
    ..5% of patients. Median survival times were 16.2 and 18.7 months for radiotherapy alone and chemotherapy-surgery respectively (P = Ns), with no long-term improvement in survival seen with combined-modality treatment...
  18. ncbi request reprint Erlotinib in previously treated non-small-cell lung cancer
    Frances A Shepherd
    Department of Medical Oncology, University Health Network, Princess Margaret Hospital Site, University of Toronto, Canada
    N Engl J Med 353:123-32. 2005
    ....
  19. doi request reprint Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21
    K Ding
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, ON, Canada
    Contemp Clin Trials 29:527-36. 2008
    ..In this paper, we discuss issues in validating drug related AEs as predictive markers of overall survival benefit. Based on our proposed approach, we showed that erlotinib induced skin rash appears to predict a survival benefit...
  20. pmc Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial
    Raymond W Jang
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 27:4268-73. 2009
    ..To aid in treatment decision making, quality-adjusted survival estimates of the JBR.10 trial were derived using a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis...
  21. ncbi request reprint Does intensive follow-up alter outcome in patients with advanced lung cancer?
    Rachel Benamore
    Department of Radiology, University Health Network and University of Toronto, Toronto, Ontario, Canada
    J Thorac Oncol 2:273-81. 2007
    ..To assess the impact of routine scanning, we compared clinical trial patients who had study-mandated scans with those treated off-study who had less intensive radiologic follow-up...
  22. doi request reprint Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer
    Martin Fruh
    Department of Medical Oncology, Princess Margaret Hospital, Toronto
    J Clin Oncol 26:3573-81. 2008
    ..This pooled analysis was undertaken to assess the efficacy and toxicity of adjuvant cisplatin-based chemotherapy in elderly patients with non-small-cell lung cancer (NSCLC)...
  23. ncbi request reprint Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial
    Janet Dancey
    Toronto Hospital, Toronto, Canada
    Lung Cancer 43:183-94. 2004
    ..Patients were randomized to docetaxel 100 mg/m2 (n=49) or, after protocol amendment, to docetaxel 75 mg/m2 (n=55), or to BSC (n=100), with Lung Cancer Symptom Scale (LCSS) and/or QLQ-C30 (with LC13 module) assessment every 3 weeks...
  24. doi request reprint Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer
    Humberto Lara-Guerra
    University Ave, Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 27:6229-36. 2009
    ..Their role in early-stage NSCLC has not been established. Our purpose was to explore the use of preoperative gefitinib in clinical stage I NSCLC to assess tumor response, toxicity, and clinical and molecular predictors of response...
  25. pmc A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    I Diaz-Padilla
    Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, University Health Network, University of Toronto, 610 University Avenue, 5 700, Toronto, Ontario M5G 2M9, Canada
    Br J Cancer 107:604-11. 2012
    ..To evaluate the safety, pharmacokinetics (PKs), and pharmacodynamics of aflibercept, and to identify the recommended phase II dose (RP2D) of aflibercept in combination with pemetrexed and cisplatin...
  26. ncbi request reprint Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience
    I Gauthier
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ont, Canada
    Lung Cancer 55:357-63. 2007
    ..Cisplatin-induced anemia may correlate with adverse events, poor quality of life (QoL), decreased adjuvant chemotherapy (ACT) dose intensity, shorter relapse-free survival (RFS) or overall survival (OS)...
  27. ncbi request reprint Angiogenesis inhibitors in the treatment of lung cancer
    F A Shepherd
    Division of Medical Oncology, Department of Medicine, Princess Margaret Hospital, 610 University Avenue, 5 104, University of Toronto, Ont, Toronto, Canada, M5G 2M9
    Lung Cancer 34:S81-9. 2001
    ..Numerous other anti-angiogenesis agents are in early clinical trials, but have not been evaluated in lung cancer yet...
  28. doi request reprint The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials
    Paul Wheatley-Price
    Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Canada
    J Thorac Oncol 5:640-8. 2010
    ..In small-cell lung cancer, women have been shown to experience greater toxicity from chemotherapy, but there are few studies of sex-related toxicity in non-small cell lung cancer (NSCLC)...
  29. pmc Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer
    Chang Qi Zhu
    University Health Network, Ontario Cancer Institute and Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 28:4417-24. 2010
    ..10 trial demonstrated benefit from adjuvant cisplatin/vinorelbine (ACT) in early-stage non-small-cell lung cancer (NSCLC). We hypothesized that expression profiling may identify stage-independent subgroups who might benefit from ACT...
  30. ncbi request reprint Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer
    Karl L Uy
    Division of Thoracic Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Thorac Cardiovasc Surg 134:188-93. 2007
    ..The surgical arm of the North American Intergroup 0139 trial was adopted as the standard treatment for patients with resectable N2 disease at the University Health Network. Results after 7 years of experience are reported...
  31. ncbi request reprint Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline
    Susanna Cheng
    Toronto Sunnybrook Regional Cancer Centre, Toronto, Canada
    J Thorac Oncol 2:348-54. 2007
    ..This clinical practice guideline, based on a systematic review, evaluates chemotherapy options for patients with relapsed small cell lung cancer (SCLC)...
  32. doi request reprint An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
    A M Horgan
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    Ann Oncol 22:1805-11. 2011
    ..Gefitinib had a better toxicity profile and greater improvements in quality of life (QoL). We undertook a cost-consequence analysis to estimate the direct medical costs of gefitinib compared with docetaxel...
  33. doi request reprint The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials
    P Wheatley-Price
    Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    Ann Oncol 21:2023-8. 2010
    ..Primary outcomes were response rate, overall survival (OS), toxicity, and dose delivery. A secondary analysis examined survival by sex in histological subgroups...
  34. ncbi request reprint Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial
    Ronald L Burkes
    Mount Sinai Hospital, University of Toronto, 600 University Avenue, Suite 1221, Toronto, Ontario, Canada M5G 1X5
    Lung Cancer 47:103-9. 2005
    ..This is a phase II study to assess the role of induction chemotherapy in the management of stage IIIA non-small-cell lung cancer (NSCLC). We are now reporting the long-term follow-up of the Toronto phase II trial...
  35. doi request reprint Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine
    Masaki Anraku
    Division of Thoracic Surgery, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
    J Thorac Cardiovasc Surg 137:441-447.e1. 2009
    ..We evaluated the outcome, long-term results, and factors affecting outcome of induction chemoradiotherapy followed by surgical resection for T4 non-small cell lung cancer invading the spine...
  36. doi request reprint A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
    Marie Florescu
    Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Hospital Site and University of Toronto, Toronto, Canada
    J Thorac Oncol 3:590-8. 2008
    ..BR.21 demonstrated significant survival benefit for non-small cell lung cancer patients receiving erlotinib compared with placebo. We undertook to characterize, by exploratory subset analysis, patients less likely to benefit from erlotinib...
  37. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations
    Akira Sakurada
    Princess Margaret Hospital and Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
    Clin Lung Cancer 7:S138-44. 2006
    ..This review summarizes the available data to date on the frequency and type of EGFR TK domain mutations and their association with clinical features, response, and survival outcome of patients treated with erlotinib and gefitinib...
  38. ncbi request reprint Erlotinib in lung cancer - molecular and clinical predictors of outcome
    Ming Sound Tsao
    University Health Network, Princess Margaret Hospital Site, and the Ontario Cancer Institute, University of Toronto, Canada
    N Engl J Med 353:133-44. 2005
    ....
  39. ncbi request reprint Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin
    D J Stewart
    Division of Medical Oncology, Ottawa Regional Cancer Centre, Ontario, Canada
    J Clin Oncol 15:1897-905. 1997
    ....
  40. ncbi request reprint The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer
    F A Shepherd
    Princess Margaret Hospital, 610 University Avenue, Suite 5 104, Toronto, Ont, Canada M5G 2M9
    Lung Cancer 30:117-25. 2000
    ..Previous reports have suggested that the day of cisplatin administration affects both toxicity and drug delivery. We undertook this retrospective analysis to determine whether it also affects response and survival...
  41. ncbi request reprint Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer
    F A Shepherd
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario
    Semin Oncol 28:30-7. 2001
    ..Miscellaneous treatments, including monoclonal antibody therapy, tamoxifen, and growth factor inhibition have not yet been shown to have a role in the treatment of SCLC. Semin Oncol 28 (suppl 4):30-37...
  42. ncbi request reprint Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials
    F A Shepherd
    Princess Margaret Hospital, University of Toronto, Ontario, Canada
    Semin Oncol 28:4-9. 2001
    ..The adverse events observed were predictable, tolerable, and manageable. These phase III trials showed that docetaxel provided clinical benefits to patients with non-small cell lung cancer...
  43. ncbi request reprint A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma
    Carol Anne Sawka
    Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada
    Biotechnol Annu Rev 11:381-9. 2005
    ..After completion of therapy, 14 patients had a complete response (30%), and 4 had a partial response (8%). Median time to progression was 9 months. At 42 months, progression-free survival was 25% and overall survival was 28%...
  44. ncbi request reprint Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
    Srikala S Sridhar
    Division of Medical Oncology, Department of Medicine of the University Health Network, Princess Margaret Hospital and the University of Toronto, Canada
    Lancet Oncol 4:397-406. 2003
    ....
  45. ncbi request reprint Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer
    Antonio L Visbal
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, ON, Canada
    Chest 128:2933-43. 2005
    ..10 trial (5-year survival rate, 15%; risk reduction for recurrence, 40%). Thus, there is compelling evidence to now recommend adjuvant platinum-based combination chemotherapy for patients after resection of early-stage NSCLC...
  46. ncbi request reprint Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, Natio
    Raymond Ng
    Department of Hematology and Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:2256-61. 2007
    ..This cost-effectiveness analysis of adjuvant chemotherapy from the perspective of Canada's public health care system was undertaken based on the JBR.10 study population...
  47. doi request reprint Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer
    Christopher Lo
    Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 28:3084-9. 2010
    ..We therefore conducted a longitudinal study to determine the course and predictors of depressive symptoms...
  48. ncbi request reprint A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung
    Natasha B Leighl
    Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Canada
    J Thorac Oncol 5:1054-9. 2010
    ..This study evaluated the efficacy and safety of intravenous aflibercept in patients with platinum- and erlotinib-resistant lung adenocarcinoma...
  49. ncbi request reprint Economic issues in lung cancer: a review
    P J Goodwin
    Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Oncol 16:3900-12. 1998
    ..It is estimated that lung cancer is responsible for 20% of all cancer care costs. Concerns exist that this expenditure is associated with questionable benefits...
  50. ncbi request reprint Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer
    F A Shepherd
    Toronto Hospital, Ontario, Canada
    Lung Cancer 17:S121-36. 1997
    ..It remains only speculative at this time as to whether manipulation of abnormal genes in malignant cells will be clinically possible, and whether treatment of this sort may be applied in an adjuvant setting...
  51. pmc Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer
    N B Leighl
    Division of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Br J Cancer 98:1769-73. 2008
    ..The DA for advanced NSCLC is feasible, acceptable to patients and improves understanding of advanced NSCLC without increasing patient anxiety...
  52. ncbi request reprint Chemotherapy and surgery for operable NSCLC
    Penelope A Bradbury
    University Health Network, Princess Margaret Hospital and University of Toronto, Toronto, OT, Canada M5G 2M9
    Lancet 369:1903-4. 2007
  53. ncbi request reprint Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer
    Natasha B Leighl
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 20:1344-52. 2002
    ..To determine the cost-effectiveness (CE) of second-line docetaxel compared with best supportive care (BSC) in the TAX 317 trial, a randomized clinical trial of second-line chemotherapy in non-small-cell lung cancer...
  54. ncbi request reprint The desire for hastened death in patients with metastatic cancer
    Gary Rodin
    Department of Psychosocial Oncology and Palliative Care, Princess Margaret Hospital, University Health Network, Toronto, Canada
    J Pain Symptom Manage 33:661-75. 2007
    ..The relative absence of a strong DHD in this sample suggests that the will to live tends to be preserved in cancer patients prior to the end of life, in spite of significant emotional and physical suffering...
  55. doi request reprint Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Chang Qi Zhu
    FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 26:4268-75. 2008
    ..To evaluate the effect of KRAS and epidermal growth factor receptor (EGFR) genotype on the response to erlotinib treatment in the BR.21, placebo-controlled trial...
  56. ncbi request reprint Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer
    Srikala S Sridhar
    Department of Medicine, Division of Hematology Oncology of the University Health Network, Princess Margaret Hospital Division, and the University of Toronto, 610 University Avenue, Suite 5 104, Toronto, ON, Canada M5G 2M9
    Lung Cancer 42:S81-91. 2003
    ..It is hoped that as our understanding of the complex process of angiogenesis increases, so will our ability to design more effective targeted therapies...
  57. ncbi request reprint Lung cancer screening with low-dose computed tomography: Canadian experience
    Heidi C Roberts
    Department of Medical Imaging, University Health Network, Toronto, ON
    Can Assoc Radiol J 58:225-35. 2007
    ..We report the results from the first 1000 baseline studies...
  58. pmc A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium
    Natasha B Leighl
    Princess Margaret Hospital Phase 2 Consortium, Ontario, Canada
    J Thorac Oncol 4:1163-9. 2009
    ..This study determined the recommended phase II dose (RP2D) of docetaxel plus GTI-2040, toxicity, and response rate in advanced non-small cell lung cancer (NSCLC)...
  59. doi request reprint Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience
    Ravi J Menezes
    Department of Medical Imaging, University Health Network, Toronto, ON, Canada
    Lung Cancer 67:177-83. 2010
    ..Baseline and annual repeat results are reported on the first 3352 participants, enrolled between June 2003 and May 2007...
  60. doi request reprint Predictors of referral for specialized psychosocial oncology care in patients with metastatic cancer: the contributions of age, distress, and marital status
    Janet Ellis
    Department of Psychosocial Oncology and Palliative Care, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 27:699-705. 2009
    ..This study examines the rate and prediction of referral for specialized psychosocial oncology care in 326 patients with metastatic GI or lung cancer...
  61. doi request reprint Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Paul Wheatley-Price
    Department of Medical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, M5G 2M9 Canada
    J Clin Oncol 26:2350-7. 2008
    ..21 established erlotinib as a standard of care in patients with non-small-cell lung cancer (NSCLC) after failure of first- or second-line chemotherapy. The current study analyzes the influence of age on outcomes in BR.21...
  62. pmc Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10
    Andrea Bezjak
    National Cancer Institute of Canada Clinical Trials Group, Cancer Centre of Southeastern Ontario, Kingston, ON, Canada
    J Clin Oncol 26:5052-9. 2008
    ..We report the QOL results of JBR.10, a North American, intergroup, randomized trial of adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC...
  63. ncbi request reprint The contribution of attachment security and social support to depressive symptoms in patients with metastatic cancer
    Gary Rodin
    Department of Psychosocial Oncology and Palliative Care, Princess Margaret Hospital, and Psychosocial Oncology and Palliative Care Research Division, Ontario Cancer Institute, University Health Network, Toronto, Canada
    Psychooncology 16:1080-91. 2007
    ....
  64. ncbi request reprint A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer
    Natasha B Leighl
    Department of Medical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    Clin Lung Cancer 5:107-12. 2003
    ..2 mg/m2 I.V. every 21 days. Antitumor activity was seen at all dose levels. This combination is well tolerated and has evidence of antitumor activity. A phase II evaluation is ongoing...
  65. ncbi request reprint A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer
    Natasha B Leighl
    Department of Medicine, Faculty of Medicine, Princess Margaret Hospital University Health Network, University of Toronto, 5 222 610 University Avenue, Toronto, Ont, Canada M5G 2M9
    Lung Cancer 51:115-21. 2006
    ..We evaluated patient utility through willingness-to-pay (WTP) for these agents in the treatment of advanced NSCLC in Canada...
  66. ncbi request reprint Adjuvant chemotherapy for resected non-small cell lung cancer
    Christopher M Booth
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Thorac Oncol 1:180-7. 2006
    ..In this review, we describe early adjuvant trials and highlight the recent landmark studies in this disease. The focus of ongoing and future research efforts is also discussed...
  67. ncbi request reprint Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18
    Natasha B Leighl
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada
    J Clin Oncol 23:2831-9. 2005
    ..In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs...
  68. ncbi request reprint Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Andrea Bezjak
    Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 24:3831-7. 2006
    ..This report describes the quality of life (QOL) findings of a randomized placebo controlled study of erlotinib, an epidermal growth factor receptor inhibitor, in patients with non-small-cell lung cancer (NSCLC)...
  69. doi request reprint EGFR mutations and lung cancer
    Gilda da Cunha Santos
    Department of Pathology, Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
    Annu Rev Pathol 6:49-69. 2011
    ..Therefore, mutation testing is mandatory to identify these patients, given that selection based only on clinico-pathologic characteristics is inadequate. We review the role of EGFR mutations in the diagnosis and management of NSCLC...
  70. ncbi request reprint Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer
    Farrah Kassam
    Division of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Ontario, Canada
    J Thorac Oncol 2:39-43. 2007
    ..This study examines whether referral patterns for adjuvant therapy in NSCLC have changed since the presentation of confirmatory trials...
  71. ncbi request reprint Should aggressive surgery ever be part of the management of small cell lung cancer?
    Thomas K Waddell
    Division of Thoracic Surgery, Department of Surgery, Toronto General Hospital, University of Toronto, 200 Elizabeth Street, EN 10 233, Toronto, Ontario, Canada
    Thorac Surg Clin 14:271-81. 2004
    ..Surgery may be considered if residual NSCLC is confirmed...
  72. doi request reprint Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer
    Anthony Brade
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 79:1395-401. 2011
    ..To evaluate the feasibility and safety of concurrent pemetrexed/cisplatin/thoracic radiotherapy followed by consolidation pemetrexed/cisplatin for unresectable Stage IIIA/B non-small-cell lung cancer (NSCLC)...
  73. pmc Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials
    T Reiman
    Department of Medicine, Dalhousie University and Department of Oncology, Saint John Regional Hospital, Saint John, NB, Canada
    Ann Oncol 23:86-93. 2012
    ..We explored this further in additional patients from JBR.10 and the other three trials...
  74. ncbi request reprint Cancer incidence among Canadian kidney transplant recipients
    P J Villeneuve
    Department of Public Health Sciences, University of Toronto, Toronto, ON, Canada
    Am J Transplant 7:941-8. 2007
    ..Our findings underscore the need for increased vigilance among kidney transplant recipients for cancers at sites where there are no population-based screening programs in place...
  75. ncbi request reprint Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
    Natasha B Leighl
    Princess Margaret Hospital University of Toronto, Department of Medicine, 5 222 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Lung Cancer 52:327-32. 2006
    ..Response rates for second-line chemotherapy are 15-25%, with a median survival of 5 months. Caelyx, a pegylated liposomal formulation of doxorubicin, may be better tolerated and has activity in SCLC...
  76. ncbi request reprint Treatment of Kaposi's sarcoma after solid organ transplantation
    F A Shepherd
    Department of Medicine, The Multi Organ Transplant Program of The Toronto Hospital, University of Toronto, Ontario, Canada
    J Clin Oncol 15:2371-7. 1997
    ....
  77. doi request reprint The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit
    P Wheatley-Price
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario
    Ann Oncol 21:232-7. 2010
    ..Previous studies reported that women survive longer than men, but experience greater toxicity, when treated for small-cell lung cancer (SCLC)...
  78. ncbi request reprint KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer
    Timothy W Corson
    Division of Applied Molecular Oncology, Ontario Cancer Institute Princess Margaret Hospital, University Health Network, University of Toronto, Canada
    Clin Cancer Res 13:3229-34. 2007
    ..Therefore, we investigated KIF14 expression in association with clinical variables and the effect of KIF14 on in vitro colony formation in non-small-cell lung carcinoma...
  79. doi request reprint Prognostic gene expression signature for squamous cell carcinoma of lung
    Chang Qi Zhu
    Ontario Cancer Institute and Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 16:5038-47. 2010
    ..This study aimed to identify and validate a gene expression signature for squamous cell carcinoma of the lung (SQCC)...
  80. doi request reprint Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials
    Lisa K Hicks
    Keenan Research Center, Li Ka Shing Knowledge Institute of St Michael s Hospital, Toronto, Ontario, Canada
    Cancer 115:5516-25. 2009
    ..However, to the authors' knowledge, the incidence of VTE in early NSCLC, predictors of VTE, and the prognostic significance of VTE in NSCLC have not been explored...
  81. doi request reprint Molecular predictive and prognostic markers in non-small-cell lung cancer
    Linda E Coate
    Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada
    Lancet Oncol 10:1001-10. 2009
    ..In this paper, we review current predictive and prognostic biomarkers in NSCLC. We assess their potential clinical use and explore recent data pertaining to genome-wide approaches for treatment selection in NSCLC...
  82. ncbi request reprint Three-gene prognostic classifier for early-stage non small-cell lung cancer
    Suzanne K Lau
    Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, Canada
    J Clin Oncol 25:5562-9. 2007
    ..However, the prognostic gene lists reported to date overlap poorly across studies, and few have been validated independently using more quantitative assay methods...
  83. ncbi request reprint Pemetrexed in the treatment of non-small cell lung cancer
    Frances A Shepherd
    University of Toronto and the Princess Margaret Hospital, Toronto, ON, Canada
    Semin Oncol 29:43-8. 2002
    ..In conclusion, pemetrexed is an active agent in the treatment of advanced NSCLC and represents a new option for the treatment of patients with this malignancy...
  84. ncbi request reprint Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker
    Chang Qi Zhu
    University Health Network, Ontario Cancer Institute and Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 10:1984-91. 2004
    ..The Skp2 gene is located on a region of chromosome 5p that is commonly overrepresented in lung cancer. The present study aimed to evaluate Skp2 abnormalities and their prognostic value in non-small cell lung cancer (NSCLC)...
  85. doi request reprint Tissue heterogeneity of EGFR mutation in lung adenocarcinoma
    Akira Sakurada
    Princess Margaret Hospital and Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
    J Thorac Oncol 3:527-9. 2008
    ..This suggests that some tumors may demonstrate intratumoral heterogeneity for the occurrence of EGFR mutation...
  86. pmc Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer
    C Q Zhu
    Division of Applied Molecular Oncology, Ontario Cancer Institute, Ontario, Toronto, Canada
    Br J Cancer 94:1452-9. 2006
    ..16, P=0.03). These data indicate that gene amplification is an important mechanism for hTERT overexpression in lung adenocarcinoma and is an independent poor prognostic marker for disease-free survival in NSCLC...
  87. doi request reprint Immunotherapy for lung cancer
    Penelope A Bradbury
    Department of Hematology and Oncology, University Health Network, Princess Margaret Hospital, and University of Toronto, Toronto, Ontario, Canada
    J Thorac Oncol 3:S164-70. 2008
    ....
  88. doi request reprint Maintenance therapy in advanced non-small cell lung cancer
    Linda E Coate
    Department of Medical Oncology and Hematology of the University Health Network, Princess Margaret Hospital Site and the University of Toronto, Toronto, Ontario, Canada
    J Thorac Oncol 5:723-34. 2010
    ..In this study, we examine the evolution of this strategy by reviewing trials investigating the main treatment paradigms used in maintenance therapy for NSCLC...
  89. ncbi request reprint Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study
    Fiona H Blackhall
    Division of Cellular and Molecular Biology, University Health Network, Ontario Cancer Institute, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada M5G 2M9
    Lung Cancer 46:197-204. 2004
    ....
  90. ncbi request reprint Influence of sex on toxicity and treatment outcome in small-cell lung cancer
    Simron Singh
    Division of Medical Oncology, Department of Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 23:850-6. 2005
    ..Studies have shown that women with other tumor types experience greater treatment toxicity, but there have been few studies of sex-related toxicity in SCLC...
  91. ncbi request reprint Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer
    Fiona H Blackhall
    Department of Medical Oncology, University Health Network Princess Margaret Hospital, University of Toronto, Toronto, Ontario, M5G 2M5 Canada
    Clin Cancer Res 9:2241-7. 2003
    ..This study was designed to examine the expression and importance of Kit, PKB/Akt, and MAPK relative to standard clinical prognostic factors in SCLC...
  92. pmc Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk
    G Liu
    Department of Medicine, Division of Medical Oncology and Hematology, Ontario Cancer Institute, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Oncogene 30:3295-304. 2011
    ..These polymorphisms thus have the potential to identify a sub-population of smokers at greater lung cancer risk, wherein this risk could be driven by an aberrant SWI/SNF chromatin-remodeling pathway...
  93. ncbi request reprint Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature
    Naveed Alam
    National Cancer Institute of Canada Clinical Trials Group, 10 Stuart Street, Kingston, Ont, Canada K7L3N6
    Lung Cancer 47:385-94. 2005
    ..Differences between nations in the perception of the risks and benefits of adjuvant chemotherapy regimens, both between physicians and patients, should be investigated further...
  94. doi request reprint Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institut
    Scott A Laurie
    The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa ON K1H 8L6, Canada
    J Clin Oncol 26:1871-8. 2008
    ..Doses of up to 45 mg/d of AZD2171 are tolerable when administered alone. This study evaluated escalating doses of AZD2171 in combination with standard chemotherapy in patients with advanced non-small-cell lung cancer...
  95. ncbi request reprint Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10
    Pascal Seve
    Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    Clin Cancer Res 13:994-9. 2007
    ..We sought to determine the effect of bTubIII on patient outcome and benefit from adjuvant chemotherapy in the JBR.10 trial...
  96. ncbi request reprint Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature
    Giannicola D'Addario
    Kantonsspital St Gallen, Departement Innere Medizin, Fachbereich Onkologie Haematologie, Rorschacherstrasse 95, 9007 St Gallen, Switzerland
    J Clin Oncol 23:2926-36. 2005
    ..This meta-analysis was performed to compare the activity, efficacy and toxicity of platinum-based versus non-platinum-based chemotherapy in patients with advanced non-small-cell lung cancer...
  97. ncbi request reprint Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21
    Gary M Clark
    OSI Pharmaceuticals, Inc, Boulder, CO 80301, USA
    Clin Lung Cancer 7:389-94. 2006
    ..21, a randomized double-blind study of 731 patients with advanced-stage non-small-cell lung cancer...
  98. ncbi request reprint Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a realistic goal?
    Fiona H Blackhall
    Christie Hospital NHS Trust, Manchester, England, United Kingdom
    Treat Respir Med 4:71-84. 2005
    ....
  99. ncbi request reprint Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer
    Rodryg Ramlau
    Regional Lung Disease Centre, Oncology Department, Poznan, Poland
    J Clin Oncol 24:2800-7. 2006
    ..This open-label, randomized, multicenter, phase III study compared oral topotecan versus intravenous (IV) docetaxel in patients with previously treated non-small-cell lung cancer (NSCLC)...
  100. ncbi request reprint Postoperative chemotherapy in nonsmall cell lung cancer: a systematic review
    Naveed Alam
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Thorac Surg 81:1926-36. 2006
    ..To date the trials restricted to stage IB or II disease have obtained the greatest survival benefits with postoperative platinum-based chemotherapy. The evidence does not support the use of postoperative radiotherapy with chemotherapy...
  101. ncbi request reprint Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy
    Frances A Shepherd
    J Clin Oncol 24:1219-20; author reply 1220-1. 2006